Wegovy expected weight loss: what clinical trials actually show

Step 1, The titration phase: why the first few months matter more for tolerance than for the scales

Wegovy does not start at the full maintenance dose. The prescriber follows a structured titration: 0.25mg weekly for the first month, stepping up through 0.5mg, 1.0mg and 1.7mg before reaching 2.4mg, each rung held for roughly four weeks. This slow escalation exists to reduce gastrointestinal side effects, not to delay results. Nausea, loose stools and indigestion are most likely in the early weeks and tend to ease as the body adjusts.

During titration, weight loss is real but modest. Most people in the STEP 1 trial were still climbing the dose ladder for the first 16 weeks. If you are tracking progress week by week, the early weeks of Wegovy look quite different from the midpoint, and that is expected. Comparing week four to week forty is not a fair test of whether the medicine is working.

Appetite reduction tends to deepen as the dose rises. By the time patients reach 2.4mg, many find portion sizes they once considered normal feel genuinely uncomfortable. That shift in satiety signals is the mechanism behind the trial numbers, Wegovy acts on GLP-1 receptors that regulate hunger and fullness, slowing gastric emptying and reducing how often and how urgently the brain signals hunger.

Step 2, The maintenance phase: where most of the weight loss is recorded

The STEP 1 trial ran for 68 weeks. Participants had typically been at the 2.4mg maintenance dose for around 52 of those weeks by the time final measurements were taken. Average weight reduction across the whole group was approximately 15%, and among those who adhered fully to both the medicine and the lifestyle programme, the figure was higher. A small proportion of participants lost more than 20% of starting body weight; others lost less than 5%. That spread is real and worth sitting with.

The NICE appraisal of semaglutide (TA875) noted this variability directly: its recommendation includes a review point at six months on the maintenance dose, with guidance to consider stopping if weight loss has not reached 5%. That is not a failure of the person, it is the prescriber using the evidence to decide whether continuing is the right call.

For a month-by-month breakdown of how that expected weight loss on Wegovy tends to accumulate, the Wegovy weight loss by month page sets out what the data shows at each stage of treatment. The trajectory is rarely linear: a plateau in month three is common even when the medicine is working.

Step 3, The 7.2mg dose: what the newer evidence adds

Since the STEP 1 results were published, Novo Nordisk has developed a higher maintenance dose. The MHRA approved 7.2mg semaglutide (initially supplied as three 2.4mg pens used in a single weekly injection) on 12 January 2026. A dedicated single-dose 7.2mg pen followed on 14 April 2026, approved for adults with a BMI of 30 or above. Trial data at this dose reported around 20.7% average weight loss over 72 weeks, approaching the results seen with tirzepatide (Mounjaro) at its highest dose in the SURMOUNT-5 head-to-head comparison.

The 7.2mg pen is a meaningful development for patients who have reached 2.4mg and want to explore whether additional loss is achievable. Specific dose and pen format availability is confirmed at consultation. For a fuller picture of how Wegovy and tirzepatide compare on weight-loss outcomes, the weight loss on Wegovy page covers the evidence side by side.

One practical note: Wegovy pens require refrigeration between 2°C and 8°C. Many people keep their current pen in the fridge door, the exact room-temperature storage window is set out in the Patient Information Leaflet, which your prescriber will direct you to.

What affects how much weight you lose on Wegovy

Trial averages describe groups, not individuals. Expected weight loss with Wegovy varies depending on starting weight, how closely a reduced-calorie diet and activity plan are followed, how well each dose is tolerated, and biological factors that no trial can fully unpick. The NICE guidance is explicit that lifestyle support alongside the medicine matters to outcomes, semaglutide is not a standalone intervention.

Conditions that prompted the prescription can also influence results. People with PCOS, for instance, may find that hormonal factors play into how their body responds; the Wegovy and PCOS page looks at what the evidence says for that group specifically. Age, existing medications and the presence of conditions like type 2 diabetes all affect the picture.

If you are weighing up whether the expected results make Wegovy the right choice for you, it is worth reading what to expect on Wegovy alongside the trial figures, the clinical data and the lived experience of treatment are both part of the decision. The Wegovy price comparison page gives context on private treatment costs, since Wegovy on the NHS is available only via specialist weight management services, with widely reported waiting lists. When you are ready to talk through your own situation, the free consultation at our weight-loss treatments page is where to start.